Sabinsa v. Herbakraft & Prakruti: Curcumin Patent Dispute Ends After Nearly 10 Years
Sabinsa Corporation pursued HERBAKRAFT and Prakruti Products over infringement of US5861415A, a patent covering curcuminoid herbal extracts. After a settlement agreement was breached, the New Jersey District Court recalculated liquidated damages — awarding $2,984,173.28, a fraction of the $15M Sabinsa sought, following nearly a decade of litigation.
A Decade-Long Curcumin Patent Battle Ends With Court-Imposed Damages
Sabinsa Corporation, a nutraceutical and botanical extract company holding US5861415A, filed suit in the District of New Jersey in July 2014 against HERBAKRAFT, Inc. and Prakruti Products Pvt., Ltd., alleging infringement through the sale of curcumin products — including Curcusol™ and herbal extracts with curcuminoid concentrations of 85%, 95% (Granular), and 95% (w/w). The case centred on the scope and enforceability of Sabinsa’s patent covering Curcuma longa-derived compositions.
The parties reached a settlement agreement during the litigation, but Prakruti subsequently breached its terms. Sabinsa sought $15,042,800 in liquidated damages under that agreement. The court, applying New Jersey law, found that amount unreasonable and conducted its own recalculation — accounting for periods of patent infringement, breach of the settlement agreement, and lost post-settlement sales — ultimately awarding $2,984,173.28 against Prakruti via default judgment. The case was formally closed in May 2024.
The duration of 3,593 days — nearly ten years — is particularly notable for a case that nominally settled, suggesting protracted enforcement proceedings followed the original resolution. The court’s willingness to recalculate and substantially reduce the contractual liquidated damages figure indicates judicial scrutiny of pre-agreed damages clauses in settlement agreements under New Jersey law. The public record does not disclose whether any separate resolution was reached with HERBAKRAFT, or the full terms of the original settlement that Prakruti breached.
Filing to Case Settled in 3593 days
3,593 days — among the longest-running patent disputes in D.N.J., spanning nearly 10 years from filing to close.
Breach of settlement: how the court resolved Sabinsa’s damages claim against Prakruti
Settlement breach triggered court-imposed liquidated damages
Although the case nominally settled, Prakruti’s subsequent breach of the settlement agreement returned the dispute to the court. Sabinsa sought to enforce a contractual liquidated damages clause. Under New Jersey law, such clauses must represent a reasonable pre-estimate of harm — the court found Sabinsa’s $15M figure failed that test and recalculated a defensible amount of $2,984,173.28, entered via default judgment.
Liquidated damages recalculatedSabinsa recovers $2.98M — but far less than its settlement clause demanded
Sabinsa secured a court-awarded damages sum and closure of the action, but received roughly 20% of its claimed $15M. The court’s recalculation was grounded in the actual periods of infringement, breach, and lost sales — not the contractual penalty as written. This outcome confirms the patent’s enforceability but signals that aggressively drafted liquidated damages clauses may face judicial reduction in New Jersey.
~20% of claimed amount awardedPrakruti faces default judgment; HERBAKRAFT outcome unclear from public record
Prakruti Products faced a default judgment of $2,984,173.28 — a consequence compounded by its failure to defend after breaching the settlement. Default judgments typically arise where a party fails to appear or respond, limiting available defences. The public record does not separately disclose the final resolution status of claims against HERBAKRAFT, Inc., leaving that aspect of the litigation’s outcome uncertain.
Default judgment enteredCurcumin IP enforcement: settlement compliance carries real financial risk
This case illustrates the enforcement risk for generic or competing curcumin extract suppliers who enter settlement agreements with established IP holders. Breaching a settlement — even when the original liquidated damages clause is later reduced — can result in substantial court-imposed liability and default judgment. Suppliers in the curcuminoid, turmeric, and botanical extract space should treat settlement obligations under US patent licences as commercially binding financial commitments.
Post-settlement enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Sabinsa Corporation | Company | Nutraceutical and botanical extract company — holder of US5861415A covering curcumin compositionsSearch in Eureka ↗ |
| Defendant | HERBAKRAFT, Inc. | Company | HERBAKRAFT Inc. (US distributor) and Prakruti Products Pvt. Ltd. (Indian manufacturer) of curcumin herbal extractsSearch in Eureka ↗ |
| Co-Defendant | Prakruti Products Pvt., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Katherine Ann Escanlar | Attorney | Counsel for Sabinsa CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Sean R. Kelly | Attorney | Counsel for Sabinsa CorporationSearch in Eureka ↗ |
| Plaintiff law firm | Saiber LLC | Law Firm | Representing Sabinsa CorporationSearch in Eureka ↗ |
| Defendant counsel | PATRICIA M. LOVE | Attorney | Counsel for HERBAKRAFT, Inc.Search in Eureka ↗ |
| Defendant law firm | HENDRICKS & HENDRICKS | Law Firm | Representing HERBAKRAFT, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s verdict language is precise and consequential: it does not simply enforce the settlement agreement as written but actively recalculates damages under New Jersey’s reasonableness standard for liquidated damages clauses. By anchoring the award to three distinct harm periods — infringement of the ‘415 patent, breach of the settlement agreement, and loss of post-settlement sales — the court signals a multi-factor approach to quantum. The $2,984,173.28 figure entered via default judgment carries full enforceability but reflects judicial restraint against punitive contractual penalties.
US5861415A — Curcuma longa extract and curcuminoid compositions
US5861415A covers compositions derived from Curcuma longa (turmeric) with specified curcuminoid concentrations, including the high-purity extract grades (85%, 95% granular, and 95% w/w) at issue in this litigation. Filed under application number US08/945311, the patent reflects Sabinsa’s early-mover position in commercialising standardised curcumin extracts for nutraceutical and dietary supplement markets. The patent sits within the natural product chemistry and botanical formulation domain, a field where IP scope is often contested on the basis of prior art from traditional use.
Strategically, US5861415A represents a foundational asset in the curcumin supply chain — one that Sabinsa has actively enforced against both distributors and manufacturers. The patent’s durability through nearly a decade of litigation, including a settlement breach and recalculated damages, suggests robust prosecution history. For any company manufacturing, importing, or distributing high-purity curcumin extracts into the US market — particularly those sourcing from India or other South Asian suppliers — this patent represents a non-trivial freedom-to-operate risk that warrants direct assessment.
Should your team run an FTO against US5861415A?
Any R&D team developing curcumin-based nutraceuticals, dietary supplements, or botanical extracts with curcuminoid purity specifications at or above 85% should treat US5861415A as a priority FTO target. This is especially critical for companies sourcing from Indian manufacturers or planning US market entry with Curcuma longa-derived products. This case confirms that Sabinsa actively enforces the patent — including post-settlement — and that US courts will support damages awards even when original contractual figures are reduced.
PatSnap Eureka’s FTO Search Agent can map the claims of US5861415A against your specific product formulations, flag overlapping curcuminoid composition patents in Sabinsa’s broader portfolio, and identify prosecution history estoppel that may limit or clarify claim scope. Use Eureka to benchmark your extract specifications against the asserted claims, and to monitor for continuation patents or related filings that could extend Sabinsa’s IP coverage in this category.
Run a freedom-to-operate analysis on US5861415A to assess your product’s exposure
Run FTO in Eureka →Similar curcumin and botanical extract patent cases in US district courts
Cases involving curcumin composition patents and nutraceutical extract IP enforcement in US district courts — relevant precedent for botanical extract suppliers and IP counsel.
What this case signals for the botanical extract IP landscape
A near-decade enforcement saga over curcumin extracts reveals durable IP risk for nutraceutical suppliers and the limits of pre-agreed damages clauses.
Settlement agreements in patent cases are not the end of litigation risk
Prakruti’s breach of a court-overseen settlement agreement triggered years of additional enforcement proceedings and ultimately a default judgment. Companies in the nutraceutical and botanical extract sector should treat post-settlement compliance as an ongoing legal obligation — with clear financial exposure if violated.
New Jersey courts will recalibrate disproportionate liquidated damages clauses
The court’s reduction from $15M to $2.98M demonstrates that New Jersey law subjects settlement-embedded penalty clauses to a reasonableness standard. IP counsel drafting enforcement settlement agreements should ensure damages figures are grounded in defensible harm estimates tied to actual infringement periods and lost sales data.
Sabinsa v HERBAKRAFT — key questions answered
The New Jersey District Court entered a default judgment of $2,984,173.28 in liquidated damages against Prakruti Products Pvt. Ltd. for breaching a settlement agreement. The court recalculated and reduced Sabinsa’s original claim of $15,042,800, finding it unreasonable under New Jersey law. The case closed in May 2024 after nearly 10 years.
Under New Jersey law, liquidated damages clauses in settlement agreements must represent a reasonable estimate of actual harm. The court found Sabinsa’s pre-agreed $15,042,800 figure failed that standard. It recalculated damages by reference to specific periods of patent infringement, settlement breach, and lost post-settlement sales, arriving at $2,984,173.28 as the defensible award.
US5861415A, held by Sabinsa Corporation, covers compositions derived from Curcuma longa (turmeric) with standardised curcuminoid content. The patent is commercially significant in the nutraceutical and dietary supplement sector because it covers high-purity curcumin extract grades used widely in health products. Sabinsa’s active enforcement history — including this nearly decade-long case — makes it a key FTO consideration for curcumin suppliers.
The products at issue included Curcuma longa and curcumin extracts with curcuminoid specifications of greater than 85%, 95% (granular), and 95% (w/w), as well as Curcusol™ and other herbal extracts. These products were allegedly sold by HERBAKRAFT and/or manufactured by Prakruti Products in a manner that infringed Sabinsa’s patent US5861415A.
A default judgment is typically entered when a party fails to appear, respond, or comply with court orders. In this case, it was entered against Prakruti Products following breach of the settlement agreement. It creates an enforceable US federal court debt of $2,984,173.28. Default judgments can affect a company’s ability to do business in the US and may be enforceable against assets in jurisdictions that recognise US court orders.
PatSnap Eureka searches patents and litigation data to answer instantly.